Pakistan’s drug regulator gave the go-ahead for the country’s first Phase 3 clinical trial for a potential Covid-19 vaccine, which is being developed by China’s CanSino Biologics (CanSino) and Beijing Institute of Biotechnology.

The trial is slated to begin next month, according to an official who will coordinate the exercise. Government-run National Institute of Health will be leading the trial for the candidate along with pharmaceutical company AJM.